Root cause focus Target NF1 protein haploinsufficiency with antisense oligonucleotide therapies to boost Neurofibromin expression, aligning with a clear disease mechanism and high unmet need for disease-modifying treatments.

Strategic partnerships Leverage current collaboration with the Gilbert Family Foundation and participation in NF conferences to accelerate access to patient communities, clinical experts, and potential co-development or funding opportunities.

Early-stage signaling Small but focused biotech likely seeking early-stage grants and collaborations; pursue government grants, SBIR opportunities, and strategic licensing deals to fuel R&D and de-risk preclinical milestones.

Regulatory readiness Position as a translational program bridging genetics to therapy with a safety and efficacy profile primed for accelerated review pathways, appealing to partners seeking faster market entry for rare disease assets.

Commercial potential NF1-focused platform with a global patient base creates potential for specialty pharma partnerships, contract research services, and co-development agreements with larger biotechs aiming to expand rare disease portfolios.